Tau Acts As an Independent Genetic Risk Factor in Pathologically Proven PD

Overview

Journal Neurobiol Aging

Publisher Elsevier

Specialties Geriatrics
Neurology
Physiology

Date 2012 Jan 7

PMID 22221882

Citations 16

Authors

Gavin Charlesworth

Sonia Gandhi

Jose M Bras

Roger A Barker

David J Burn

Patrick F Chinnery

Stephen M Gentleman

Rita Guerreiro

John Hardy

Janice L Holton

Andrew Lees

Karen Morrison

Una-Marie Sheerin

Nigel Williams

Huw Morris

Tamas Revesz

Nicholas W Wood

Affiliations

Soon will be listed here.

Abstract

MAPT has been repeatedly linked with Parkinson's disease (PD) in association studies. Although tau deposition may be seen in PD, its relevance to the pathogenesis of the condition remains unclear. The presence of tau-positive inclusions is, however, the defining feature of progressive supranuclear palsy (PSP), which may often be clinically misdiagnosed as idiopathic PD. On a genetic level, variants in MAPT are the strongest risk factor for PSP. These facts raise the question whether the MAPT association in PD results from contamination with unrecognized cases of PSP. Using only neuropathologically proven PD, we show that the MAPT association remains and is independent of the PSP Association.

Citing Articles

Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies.

Nazeen S, Wang X, Zielinski D, Lam I, Hallacli E, Xu P bioRxiv. 2024; .

PMID: 38496508 PMC: 10942362. DOI: 10.1101/2024.03.03.583145.

Extracellular Vesicles for the Diagnosis and Treatment of Parkinson's Disease.

Upadhya R, Shetty A Aging Dis. 2021; 12(6):1438-1450.

PMID: 34527420 PMC: 8407884. DOI: 10.14336/AD.2021.0516.

FaptaSyme: A Strategy for Converting a Monomer/Oligomer-Nonselective Aptameric Sensor into an Oligomer-Selective One.

Evangelista B, Kim Y, Kolpashchikov D Chembiochem. 2018; .

PMID: 29700982 PMC: 6422747. DOI: 10.1002/cbic.201800017.

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.

Gerson J, Farmer K, Henson N, Castillo-Carranza D, Murillo M, Sengupta U Mol Neurodegener. 2018; 13(1):13.

PMID: 29544548 PMC: 5856311. DOI: 10.1186/s13024-018-0245-9.

Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect?.

Redensek S, Trost M, Dolzan V Front Aging Neurosci. 2017; 9:20.

PMID: 28239348 PMC: 5301007. DOI: 10.3389/fnagi.2017.00020.

References

Spencer C, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G . Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet. 2010; 20(2):345-53. PMC: 3005904. DOI: 10.1093/hmg/ddq469. View

Simon-Sanchez J, Schulte C, Bras J, Sharma M, Gibbs J, Berg D . Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009; 41(12):1308-12. PMC: 2787725. DOI: 10.1038/ng.487. View

Newman E, Breen K, Patterson J, Hadley D, Grosset K, Grosset D . Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord. 2009; 24(16):2379-85. DOI: 10.1002/mds.22829. View

Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M . Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009; 41(12):1303-7. DOI: 10.1038/ng.485. View

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

Goris A, Williams-Gray C, Clark G, Foltynie T, Lewis S, Brown J . Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol. 2007; 62(2):145-53. DOI: 10.1002/ana.21192. View

de Silva R, Hardy J, Crook J, Khan N, Graham E, Morris C . The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neurosci Lett. 2002; 330(2):201-3. DOI: 10.1016/s0304-3940(02)00742-5. View

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

Williams-Gray C, Evans J, Goris A, Foltynie T, Ban M, Robbins T . The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009; 132(Pt 11):2958-69. DOI: 10.1093/brain/awp245. View

10.

Devine M, Lewis P . Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2. FEBS J. 2008; 275(23):5748-57. DOI: 10.1111/j.1742-4658.2008.06707.x. View

11.

Naj A, Jun G, Beecham G, Wang L, Vardarajan B, Buros J . Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011; 43(5):436-41. PMC: 3090745. DOI: 10.1038/ng.801. View

12.

Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K . Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007; 1184:284-94. DOI: 10.1016/j.brainres.2007.09.048. View

13.

Myers A, Pittman A, Zhao A, Rohrer K, Kaleem M, Marlowe L . The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis. 2006; 25(3):561-70. DOI: 10.1016/j.nbd.2006.10.018. View

14.

Nalls M, Plagnol V, Hernandez D, Sharma M, Sheerin U, Saad M . Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011; 377(9766):641-9. PMC: 3696507. DOI: 10.1016/S0140-6736(10)62345-8. View

15.

Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J . Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999; 8(4):711-5. DOI: 10.1093/hmg/8.4.711. View

16.

Hauw J, Daniel S, Dickson D, Horoupian D, Jellinger K, Lantos P . Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994; 44(11):2015-9. DOI: 10.1212/wnl.44.11.2015. View

17.

Haggerty T, Credle J, Rodriguez O, Wills J, Oaks A, Masliah E . Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci. 2011; 33(9):1598-610. PMC: 3086951. DOI: 10.1111/j.1460-9568.2011.07660.x. View

18.

Braak H, Del Tredici K, Rub U, de Vos R, Jansen Steur E, Braak E . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2002; 24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. View

19.

Wider C, Vilarino-Guell C, Jasinska-Myga B, Heckman M, Soto-Ortolaza A, Cobb S . Association of the MAPT locus with Parkinson's disease. Eur J Neurol. 2009; 17(3):483-6. PMC: 3906622. DOI: 10.1111/j.1468-1331.2009.02847.x. View

20.

. A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet. 2011; 7(6):e1002142. PMC: 3128098. DOI: 10.1371/journal.pgen.1002142. View